TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22111914
Drug: Laparoscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic surgery with fast track perioperative treatment and Xelox chemotherapy
Study: 22111914
Drug: Open surgery
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open surgery with fast track perioperative treatment and Xelox chemotherapy
Study: 22111914
Drug: Laparoscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic surgery with conventional perioperative treatment and mFolfox6 chemotherapy
Study: 22111914
Drug: Open surgery
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open surgery with conventional perioperative treatment and mFolfox6 chemotherapy
Study: 19395457
Drug: Atacicept (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 x 9 mg/kg)
Study: 16467018
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg or 50 mg twice weekly (BIW) or 25 mg once weekly
Study: 16467018
Drug: Placebo (original
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (original placebo patients received 25 mg BIW for the final 12 weeks of the double‐blind period)
Study: 14748943
Drug: Micronised, dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised, dispersible ferric pyrophosphate (5 mg Fe) in infant cereal
Study: 14748943
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (5 mg Fe) in infant cereal
Study: 14748943
Drug: Micronised, dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronised, dispersible ferric pyrophosphate (5 mg Fe) in yoghurt drink
Study: 14748943
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (5 mg Fe) in yoghurt drink
Study: 9369270
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 5.0 ng Ang II x kg(‐1) x min(‐1) (pressor dose)
Study: 9369270
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 1.0 ng Ang II x kg(‐1) x min(‐1) (subpressor dose)
Study: 9369270
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of Ang II during oral glucose tolerance test
Study: 3883177
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin 2.4 million U weekly for three weeks (total 7.2 million U)
Study: 3883177
Drug: Intravenous penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous penicillin G 20 million U a day for 10 days
Study: 30636561
Drug: Low-dose prasugrel
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prasugrel (5 mg daily)
Study: 30547863
Drug: Sous vide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sous vide preparation of pork roast from an organic farm
Study: 30547863
Drug: Sous vide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sous vide preparation of pork roast from an ordinary pig
Study: 26633806
Drug: CTZ (Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTZ (Chemotherapy + Zoledronic Acid)
Study: 26633806
Drug: CT (Chemotherapy)
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (Chemotherapy)
Study: 26633806
Drug: CTZ (Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTZ (Chemotherapy + Zoledronic Acid) in postmenopausal patients
Study: 26633806
Drug: CT (Chemotherapy)
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (Chemotherapy) in postmenopausal patients
Study: 26633806
Drug: CTZ (Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTZ (Chemotherapy + Zoledronic Acid) in triple-negative breast cancer patients
Study: 26633806
Drug: CT (Chemotherapy)
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (Chemotherapy) in triple-negative breast cancer patients
Study: 18644036
Drug: almotriptan 12.5
Normalized name: almotriptan 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: almotriptan 12.5 mg combined with aceclofenac 100 mg
Study: 17176279
Drug: IM syntometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM syntometrine (1 ml, a mixture of 5 iu oxytocin and 0.5 mg ergometrine)
Study: 10761802
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (Group 1)
Study: 10761802
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (Group 2)
Study: 26068323
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg.kg‐1)
Study: 3779343
Drug: Placebo (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (225 mg methylcellulose)
Study: 27903564
Drug: Tailored intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tailored intervention based on a discussion informed by responses to the MAQ, Beliefs about Medicines Questionnaire‐Specific and Brief Illness Perception Questionnaire.
Study: 21110503
Drug: Antibiotic eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic eye drops, used 4 times a day for 5 days before surgery
Study: 7855383
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and nicotinamide (3 g/day for 1 year)
Study: 1018027
Drug: In-patient rest
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-patient rest in bed (IP) for six months followed by out-patient treatment
Study: 1018027
Drug: Ambulatory out-patient
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ambulatory out-patient treatment (OP) from the start
Study: 1018027
Drug: Out-patient treatment
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-patient treatment with a plaster-of-Paris jacket (J) for nine months
Study: 1018027
Drug: Ambulatory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory treatment without any support (No J)
Study: 1018027
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with PAS and isoniazid for eighteen months supplemented with streptomycin for the first three months (SPH)
Study: 1018027
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with PAS and isoniazid for eighteen months without the supplement (PH)
Study: 31033046
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL flush volume
Study: 31033046
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL flush volume
Study: 31033046
Drug: 6 hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 hourly flushing frequency
Study: 31033046
Drug: 24 hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hourly flushing frequency
Study: 18202964
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined conjugated estrogens (CE)/medroxyprogesterone acetate (MPA) at doses of 0.625/2.5 mg/day, 0.45/1.5 mg/day, and 0.3/1.5 mg/day for 6 months (6 continuous 28-day cycles)
Study: 15633440
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (TT)
Study: 29528692
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor injections
Study: 28118425
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injections
Study: 25437217
Drug: Early nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early nutritional support via the parenteral route
Study: 22796236
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of HCG (HCG group)
Study: 20114095
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation (8 treatments)
Study: 20114095
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation (16 treatments)
Study: 20114095
Drug: Light massage
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light massage (8 treatments)
Study: 20114095
Drug: Light massage
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light massage (16 treatments)
Study: 8747677
Drug: Psychophysiological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychophysiological therapy (PP)
Study: 31489910
Drug: 9 meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 meals daily (9M)
Study: 31489910
Drug: 3 meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 meals daily (3M)
Study: 23213288
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS combined with speech and language therapy
Study: 23213288
Drug: Sham rTMS
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham rTMS combined with speech and language therapy
Study: 8930424
Drug: valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 320 mg
Study: 17923463
Drug: valsartan/hydrochlorothiazide 320
Normalized name: valsartan/hydrochlorothiazide 320 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan/hydrochlorothiazide 320 mg/12.5 mg
Study: 9164358
Drug: Salmeterol 42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 42 micrograms twice daily
Study: 2199801
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Simvastatin + Cholestyramine)
Study: 374178
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg daily for 3 weeks
Study: 31947163
Drug: Near Infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Near Infrared (NIR) spectrometric monitoring of lactate levels using solution samples with varying concentrations of sodium lactate in isotonic Phosphate Buffer Solution (PBS) at pH 7.4.
Study: 26467096
Drug: Weekly automated
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly automated text messages (SMS-Track) reporting the number of days with bothersome LBP (0-7 days) over 1 year.
Study: 11137102
Drug: Garlic preparation
Normalized name: garlic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic preparation (500 mg dehydrated garlic powder/day)
Study: 11137102
Drug: Garlic preparation
Normalized name: garlic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic preparation (1000 mg dehydrated garlic powder/day)
Study: 8061852
Drug: Spirapril (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril (3, 6, 12, or 24 mg once daily)
Study: 8061852
Drug: Spirapril (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril (all doses)
Study: 3243924
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg prazosin
Study: 3243924
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg prazosin
Study: 3243924
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg prazosin
Study: 3243924
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage ranges (6 mg and 12 mg)
Study: 29698917
Drug: Support Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support Therapy (ST)
Study: 16161729
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (additional time in treatment)
Study: 12892455
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) in D(+) patients (n=12)
Study: 12892455
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) in D(-) patients (n=7)
Study: 10230189
Drug: Sertraline (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (average dose of 167 mg/day)
Study: 8558315
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate co‐ingested with 40 g of a cereal product containing 16 g wheat bran
Study: 1991366
Drug: Colestipol-niacin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol-niacin therapy plus diet
Study: 6576807
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg vaginal prostaglandin E2 pessaries
Study: 367426
Drug: intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous oxytocin
Study: 30478008
Drug: Valacyclovir (1.5 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (1.5 g BID)
Study: 29687335
Drug: PF ophthalmic
Normalized name: GenTeal PF Ophthalmic Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF ophthalmic solution containing HA 0.4% and TAU 0.5%, QID
Study: 29687335
Drug: PF ophthalmic
Normalized name: GenTeal PF Ophthalmic Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF ophthalmic solution containing HA 0.2%, QID
Study: 22278094
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) application
Study: 12536591
Drug: 131I plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I plus thyrostatic medication (PTU)
Study: 9696456
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg morphine (p.o.)
Study: 9696456
Drug: 170 mg
Normalized name: mannitol 170 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 170 mg codeine (p.o.)
Study: 2526767
Drug: Nicotinamide 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide 1 g/day
Study: 987761
Drug: Adjuvant chemoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemoimmunotherapy (cyclophosphamide, methotrexate, fluorouracil, and BCG vaccine +/− an irradiated allogeneic tumor cell vaccine)
Study: 26865048
Drug: HZ/su (Shingrix)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su (Shingrix) vaccine
Study: 26865048
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection site pain and swelling
Study: 18695765
Drug: DTPa-IPV/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV/Hib vaccine co-administered with rotavirus vaccine
Study: 15041394
Drug: Daclizumab 50
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab 50 mg (two doses on day 0 and day 14)
Study: 15041394
Drug: Daclizumab 25
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 25 mg (two doses on day 0 and day 14)
Study: 15041394
Drug: Basiliximab 20
Normalized name: basiliximab 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab 20 mg (two doses on day 0 and day 4)
Study: 12511059
Drug: Enhanced methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced methadone treatment primarily cognitive‐behavioral therapy (CBT) for cocaine use
Study: 10688158
Drug: Risperidone 4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4 mg
Study: 10622347
Drug: Risperidone 8
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone 8 mg
Study: 1172753
Drug: 10% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% potassium chloride solution
Study: 1172753
Drug: Waxy-matrix potassium
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waxy-matrix potassium chloride tablet
Study: 16143120
Drug: Certolizumab 200
Normalized name: certolizumab 200 mg subcutaneous kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certolizumab 200 mg
Study: 27873502
Drug: Intravenous urapidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous urapidil
Study: 25927360
Drug: JAIVAC-1 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAIVAC-1 (10 μg, 25 μg, and 50 μg of each antigen)
Study: 25927360
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (standard dosage)
Study: 21781475
Drug: 15 ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ± 5 mg/kg salt iodization
Study: 21781475
Drug: 35 ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 ± 5 mg/kg salt iodization
Study: 11736779
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 1 microg x kg(‐1) intra‐operatively
Study: 11736779
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 100 microg x kg(‐1) at induction
Study: 8107618
Drug: Progesterone administered
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone administered by nasal spray (34 mg daily for 5-7 days) with oral estrogens for 3-4 weeks
Study: 8107618
Drug: Progesterone administered
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone administered by nasal spray (34 mg daily for 6 days) without estrogens
Study: 3632375
Drug: Progabide (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progabide (45 mg/kg)
Study: 21814174
Drug: Conventional PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional PD solutions
Study: 18787222
Drug: Daclizumab (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (intravenous loading dose, 2 mg/kg, then 1 mg/kg) every 2 weeks, added to stable-dose TAA through Week 12.
Study: 18787222
Drug: Placebo every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 2 weeks, added to stable-dose TAA through Week 12.
Study: 15116008
Drug: Dideco Lilliput
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideco Lilliput 1 Oxygenator with 750 mL priming volume
Study: 15116008
Drug: Dideco Lilliput
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dideco Lilliput 1 Oxygenator with 450 mL priming volume
Study: 9039945
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (1500 IU of anti‐HBs)
Study: 9039945
Drug: Intramuscular immunoglobulin
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular immunoglobulin (1000 IU of anti‐HBs)
Study: 9039945
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from intravenous to intramuscular immunoglobulin
Study: 3381992
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g dipyrone
Study: 7951343
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg butylscopolamine
Study: 3306163
Drug: Propranolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (20 mg every 6 hours)
Study: 3306163
Drug: Digoxin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.5 mg followed by 0.25 mg daily)
Study: 28574274
Drug: Transition strategies
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transition strategies from intravenous to oral P2Y12 receptor antagonists
Study: 27714002
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling with currants (two fruit servings, 36 g per day)
Study: 24856557
Drug: S-adenosyl methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl methionine (SAMe) 1600-3200mg/daily
Study: 24856557
Drug: Escitalopram 10-20mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10-20mg/daily
Study: 22156333
Drug: Conventional IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional IV nurse‐administered as‐needed (PRN) therapy
Study: 14750614
Drug: Telithromycin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telithromycin (800 mg once daily for 5 days)
Study: 17404000
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg twice daily for 5 days)
Study: 12555509
Drug: Moxonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.2 mg od)
Study: 12555509
Drug: Rilmenidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (1 mg od)
Study: 9430987
Drug: AAACa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAACa (200 mg calcium)
Study: 9430987
Drug: Milk (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (200 ml after breakfast, supper, and at bedtime)
Study: 9430987
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no calcium supplement)
Study: 8007703
Drug: 5-year administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-year administration of 4-HPR
Study: 2831594
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with a non-specific adjuvant
Study: 31566800
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to first analgesic medication
Study: 23846486
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (400 mg or 800 mg of total EGCG daily, administered in split doses)
Study: 18419948
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg intravenous injection based on psychological nursing intervention